Heterocyclic compounds and uses thereof
US-2016333008-A1 · Nov 17, 2016 · US
Tyrosine kinase inhibitors
US10434096B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10434096-B2 |
| Application number | US-201816151959-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 4, 2018 |
| Priority date | Jul 8, 2016 |
| Publication date | Oct 8, 2019 |
| Grant date | Oct 8, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, Y and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.
First claim
Opening claim text (preview).
What is claimed: 1. A compound having the structure formula or a pharmaceutically acceptable salt, or N-oxide thereof, or a solvate or hydrate thereof. 2. A pharmaceutical composition comprising a pharmaceutically acceptable diluent, carrier, or excipient and a compound according to claim 1 . 3. A method of inhibiting a cellular TAM receptor, the method comprising contacting a cell comprising a TAM receptor with a compound according to claim 1 , or a composition of claim 2 . 4. The method of claim 3 , wherein the TAM receptor is a Tyro receptor, an Axl receptor, or a Mer receptor. 5. A method for treating a disease or condition mediated by or involving the TAM receptor family in a subject in need thereof, comprising administering an effective TAM receptor inhibiting amount of a compound of claim 1 , or a composition of claim 2 , wherein the disease or condition is a hematological neoplasm. 6. The method of claim 5 , wherein the hematological neoplasms is acute myeloid leukemia AML.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
specific for leukemia · CPC title
Antineoplastic agents · CPC title
ortho- or peri-condensed with heterocyclic rings · CPC title
Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10434096B2 cover?
- Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, Y and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellu…
- Who is the assignee on this patent?
- Rigel Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4545. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).